Conexeu Sciences is trading 11.03% higher at $3.67, with no clear company-specific catalyst identified for October 14, 2026. - The latest located company announcement was October 6, describing progress toward a planned FDA 510(k) submission in the first quarter of 2027; it was not a new announcement today. - Biotech was down 2.01%, so the sector context does not explain the upward move.